Valuation: Avicanna Inc.

Market Cap 18.14M 12.88M 11.31M 10.52M 9.66M 1.24B 18.42M 125M 48.82M 610M 48.36M 47.32M 2.11B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 17.86M 12.68M 11.14M 10.36M 9.51M 1.22B 18.14M 123M 48.06M 600M 47.61M 46.59M 2.08B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day+3.75%
1 week+3.97%
Current month+9.69%
1 month+12.54%
3 months-6.92%
6 months-39.64%
Current year-38.56%
1 week 0.09
Extreme 0.0854
0.1
1 month 0.07
Extreme 0.0684
0.11
Current year 0.07
Extreme 0.0684
0.18
1 year 0.07
Extreme 0.0684
0.24
3 years 0.07
Extreme 0.0684
0.53
5 years 0.07
Extreme 0.0684
1.19
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 2015-04-30
Chief Executive Officer 39 2016-11-25
Director of Finance/CFO - 2025-09-14
Director TitleAgeSince
Chairman 39 2016-11-25
Director/Board Member - 2018-10-21
Director/Board Member - 2025-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%+3.97% - - 12.87M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.37%+38.15% 26.77B
+0.47%-2.74% - - 16.66B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average +0.58%+0.99%+54.97%+107.37% 27.09B
Weighted average by Cap. +0.46%+1.10%+75.57%+137.02%

Financials

2024 2025
Net sales 25.46M 18.08M 15.88M 14.77M 13.55M 1.74B 25.85M 175M 68.51M 856M 67.87M 66.4M 2.96B 25.48M 18.09M 15.89M 14.78M 13.56M 1.74B 25.87M 175M 68.56M 857M 67.92M 66.45M 2.96B
Net income -3.62M -2.57M -2.26M -2.1M -1.93M -247M -3.67M -24.92M -9.73M -122M -9.64M -9.44M -421M -2.76M -1.96M -1.72M -1.6M -1.47M -189M -2.8M -19M -7.42M -92.76M -7.36M -7.2M -321M
Net Debt -339K -241K -211K -197K -180K -23.17M -344K -2.33M -912K -11.39M -903K -884K -39.38M -281K -199K -175K -163K -149K -19.19M -285K -1.93M -755K -9.43M -748K -732K -32.62M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
26-07-24 US$0.0996 +3.75% 30,000
26-07-23 US$0.0960 -5.35% 10,000
26-07-22 US$0.1014 +9.65% 4,000
26-07-21 US$0.0925 -3.44% 44,100
26-07-17 US$0.0958 +10.49% 13,500